Crystal structure of human kynurenine aminotransferase II, a drug target for the treatment of schizophrenia

Franca Rossi, Silvia Garavaglia, Valeria Montalbano, Martin A. Walsh, Menico Rizzi

Risultato della ricerca: Contributo su rivistaArticolo in rivistapeer review

Abstract

Kynurenic acid is an endogenous neuroactive compound whose unbalancing is involved in the pathogenesis and progression of several neurological diseases. Kynurenic acid synthesis in the human brain is sustained by the catalytic activity of two kynurenine aminotransferases, hKAT I and hKAT II. A wealth of pharmacological data highlight hKAT II as a sensible target for the treatment of neuropathological conditions characterized by a kynurenic acid excess, such as schizophrenia and cognitive impairment. We have solved the structure of human KAT II by means of the single-wavelength anomalous dispersion method at 2.3-Å resolution. Although closely resembling the classical aminotransferase fold, the hKATII architecture displays unique features. Structural comparison with a prototypical aspartate aminotransferase reveals a novel antiparallel strand-loop-strand motif that forms an unprecedented intersubunit β-sheet in the functional hKAT II dimer. Moreover, the N-terminal regions of hKAT II and aspartate aminotransferase appear to have converged to highly similar although 2-fold symmetry-related conformations, which fulfill the same functional role. A detailed structural comparison of hKAT I and hKAT II reveals a larger and more aliphatic character to the active site of hKAT II due to the absence of the aromatic cage involved in ligand binding in hKAT I. The observed structural differences could be exploited for the rational design of highly selective hKAT II inhibitors.

Lingua originaleInglese
pagine (da-a)3559-3566
Numero di pagine8
RivistaJournal of Biological Chemistry
Volume283
Numero di pubblicazione6
DOI
Stato di pubblicazionePubblicato - 8 feb 2008

Fingerprint

Entra nei temi di ricerca di 'Crystal structure of human kynurenine aminotransferase II, a drug target for the treatment of schizophrenia'. Insieme formano una fingerprint unica.

Cita questo